Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 1,200 shares, a decrease of 91.0% from the February 13th total of 13,400 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 33,700 shares, the short-interest ratio is currently 0.0 days.

Artelo Biosciences Trading Down 2.1 %

ARTL stock opened at $0.95 on Thursday. Artelo Biosciences has a 1-year low of $0.91 and a 1-year high of $1.70. The business’s 50 day moving average is $1.16 and its 200-day moving average is $1.14. The firm has a market cap of $3.12 million, a P/E ratio of -0.33 and a beta of 1.06.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43). Sell-side analysts forecast that Artelo Biosciences will post -2.62 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ARTL. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a report on Tuesday, March 4th. LADENBURG THALM/SH SH raised shares of Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Artelo Biosciences in a report on Thursday, February 27th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.